Lian-Jing Cao1, Yi-Jun Zhang1,2, Si-Qi Dong1, Xi-Zhao Li1, Xia-Ting Tong1, Dong Chen1,3, Zi-Yi Wu1, Xiao-Hui Zheng1, Wen-Qiong Xue1, Wei-Hua Jia4, Jiang-Bo Zhang5. 1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center, Guangzhou, China. 2. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China. 3. Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. 4. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center, Guangzhou, China. jiawh@sysucc.org.cn. 5. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center, Guangzhou, China. zhangjb@sysucc.org.cn.
Abstract
BACKGROUND: Distant metastasis is the leading cause of death for esophageal squamous cell carcinoma (ESCC) with limited treatment options and unsatisfactory effectiveness. Bromodomain (BRD) containing proteins are emerging targets for cancer therapy with promising effects. As a unique member of BRD family, the function and molecular mechanism of ATAD2 in cancer development is seldomly investigated. METHODS: The clinical impact of ATAD2 was assessed both at RNA and protein level in 75 and 112 ESCC patients separately. The biological function of ATAD2 was investigated in vitro and in vivo. Signaling pathway and downstream effectors of ATAD2 were identified by RNA sequencing, luciferase reporter, co-immunoprecipitation, chromatin immunoprecipitation, immunofluorescence and western blot assay. RESULTS: We found that elevated ATAD2 expression was significantly associated with lymph node metastasis, advanced clinical stage as well as poor survival of ESCC patients. Silencing ATAD2 significantly suppressed ESCC cell migration and invasion in vitro, and inhibited tumor growth and lung metastasis in vivo. Mechanically, we identified a new cofactor, C/EBPβ. ATAD2 directly interacted with C/EBPβ and promoted its nuclear translocation, which directly bound to the promoter region of TGF-β1 and activated its expression. Further, we demonstrated that TGF-β1 activated its downstream effectors in a Smad3 dependent manner. In addition, we further found that ATAD2 promoted ESCC metastasis through TGF-β signaling induced Snail expression and the subsequent epithelial-mesenchymal transition. CONCLUSION: Our findings demonstrated the pro-metastatic function of ATAD2 and uncovered the new molecular mechanism by regulating C/EBPβ/TGF-β1/Smad3/Snail signaling pathway, thus providing a potential target for the treatment of ESCC metastasis.
BACKGROUND: Distant metastasis is the leading cause of death for esophageal squamous cell carcinoma (ESCC) with limited treatment options and unsatisfactory effectiveness. Bromodomain (BRD) containing proteins are emerging targets for cancer therapy with promising effects. As a unique member of BRD family, the function and molecular mechanism of ATAD2 in cancer development is seldomly investigated. METHODS: The clinical impact of ATAD2 was assessed both at RNA and protein level in 75 and 112 ESCC patients separately. The biological function of ATAD2 was investigated in vitro and in vivo. Signaling pathway and downstream effectors of ATAD2 were identified by RNA sequencing, luciferase reporter, co-immunoprecipitation, chromatin immunoprecipitation, immunofluorescence and western blot assay. RESULTS: We found that elevated ATAD2 expression was significantly associated with lymph node metastasis, advanced clinical stage as well as poor survival of ESCC patients. Silencing ATAD2 significantly suppressed ESCC cell migration and invasion in vitro, and inhibited tumor growth and lung metastasis in vivo. Mechanically, we identified a new cofactor, C/EBPβ. ATAD2 directly interacted with C/EBPβ and promoted its nuclear translocation, which directly bound to the promoter region of TGF-β1 and activated its expression. Further, we demonstrated that TGF-β1 activated its downstream effectors in a Smad3 dependent manner. In addition, we further found that ATAD2 promoted ESCC metastasis through TGF-β signaling induced Snail expression and the subsequent epithelial-mesenchymal transition. CONCLUSION: Our findings demonstrated the pro-metastatic function of ATAD2 and uncovered the new molecular mechanism by regulating C/EBPβ/TGF-β1/Smad3/Snail signaling pathway, thus providing a potential target for the treatment of ESCC metastasis.
Authors: Hanwen Bai; Akdes Serin Harmancı; E Zeynep Erson-Omay; Jie Li; Süleyman Coşkun; Matthias Simon; Boris Krischek; Koray Özduman; S Bülent Omay; Eric A Sorensen; Şevin Turcan; Mehmet Bakırcığlu; Geneive Carrión-Grant; Phillip B Murray; Victoria E Clark; A Gulhan Ercan-Sencicek; James Knight; Leman Sencar; Selin Altınok; Leon D Kaulen; Burcu Gülez; Marco Timmer; Johannes Schramm; Ketu Mishra-Gorur; Octavian Henegariu; Jennifer Moliterno; Angeliki Louvi; Timothy A Chan; Stacey L Tannheimer; M Necmettin Pamir; Alexander O Vortmeyer; Kaya Bilguvar; Katsuhito Yasuno; Murat Günel Journal: Nat Genet Date: 2015-11-30 Impact factor: 38.330
Authors: Emily J Faivre; Keith F McDaniel; Daniel H Albert; Srinivasa R Mantena; Joshua P Plotnik; Denise Wilcox; Lu Zhang; Mai H Bui; George S Sheppard; Le Wang; Vasudha Sehgal; Xiaoyu Lin; Xiaoli Huang; Xin Lu; Tamar Uziel; Paul Hessler; Lloyd T Lam; Richard J Bellin; Gaurav Mehta; Steve Fidanze; John K Pratt; Dachun Liu; Lisa A Hasvold; Chaohong Sun; Sanjay C Panchal; John J Nicolette; Stacey L Fossey; Chang H Park; Kenton Longenecker; Lance Bigelow; Maricel Torrent; Saul H Rosenberg; Warren M Kati; Yu Shen Journal: Nature Date: 2020-01-22 Impact factor: 49.962
Authors: Panagis Filippakopoulos; Sarah Picaud; Maria Mangos; Tracy Keates; Jean-Philippe Lambert; Dalia Barsyte-Lovejoy; Ildiko Felletar; Rudolf Volkmer; Susanne Müller; Tony Pawson; Anne-Claude Gingras; Cheryl H Arrowsmith; Stefan Knapp Journal: Cell Date: 2012-03-30 Impact factor: 41.582